The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
Open accessAbstract
Background Results of cohort studies and mathematical models have suggested that increased coverage with highly active antiretroviral therapy (HAART) could reduce HIV transmission. We aimed to estimate the association between plasma HIV-1 viral load, HAART coverage, and number of new cases of HIV in the population of a Canadian province.Methods We undertook a population-based study of HAART coverage and HIV transmission in British Columbia, Canada. Data for number of HIV tests done and new HIV diagnoses were obtained from the British Columbia Centre for Disease Control. Data for viral load, CD4 cell count, and HAART use were extracted from the British Columbia Centre for Excellence in HIV/AIDS population-based registries. We modelled trends of new HIV-positive tests and number of individuals on HAART using generalised additive models. Poisson log-linear regression models were used to estimate the association between new HIV diagnoses and viral load, year, and number of individuals on HAART.Findings Between 1996 and 2009, the number of individuals actively receiving HAART increased from 837 to 5413 (547% increase; p=0.002), and the number of new HIV diagnoses fell from 702 to 338 per year (52% decrease; p=0.001). The overall correlation between number of individuals on HAART and number of individuals newly testing positive for HIV per year was -0.89 (p<0.0001). For every 100 additional individuals on HAART, the number of new HIV cases decreased by a factor of 0.97 (95% CI 0.96-0.98), and per 1 log(10) decrease in viral load, the number of new HIV cases decreased by a factor of 0.86 (0.75-0.98).Interpretation We have shown a strong population-level association between increasing HAART coverage, decreased viral load, and decreased number of new HIV diagnoses per year. Our results support the proposed secondary benefit of HAART used within existing medical guidelines to reduce HIV transmission.Funding Ministry of Health Services and Ministry of Healthy Living and Sport, Province of British Columbia; US National Institute on Drug Abuse; US National Institutes of Health; Canadian Institutes of Health Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For HIV and opioid addictions, innovative, wellresourced treatment delivery platforms and harm-reduction initiatives for injection drug use have made specific and significant impacts on HIV transmission and on mortality related to opioid overdose. 10,11”
From The Hotel Study—Clinical and Health Service Effectiveness in a Cohort of Homeless or Marginally Housed Persons (2017) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1
Quinn, T. C., Wawer, M. J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., Meehan, M. O., Lutalo, T., & Gray, R. H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421303 · Cited by 3,020
Granich, R. M., Gilks, C. F., Dye, C., De Cock, K. M., & Williams, B. G. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61697-9 · Cited by 1,988
Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.
Breslow, N. E., & Day, N. E. (1987) · PubMed · Cited by 1,684
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
De Cock, K. M., Fowler, M. G., Mercier, E., de Vincenzi, I., Saba, J., Hoff, E., Alnwick, D. J., Rogers, M., & Shaffer, N. (2000) · JAMA · doi:10.1001/jama.283.9.1175 · Cited by 1,101
Attia, S., Egger, M., Müller, M., Zwahlen, M., & Low, N. (2009) · AIDS · doi:10.1097/qad.0b013e32832b7dca · Cited by 1,001
Cited by
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
“(%)¶** 59/1569 (4) 73/1576 (5) 60/1572 (4) 52/1573 (3) 62/1569 (4) 73/1571 (5)”
Samji, H., Cescon, A., Hogg, R. S., Modur, S. P., Althoff, K. N., Buchacz, K., Burchell, A. N., Cohen, M., Gebo, K. A., Gill, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081355 · Cited by 1,417
“ART is effective in increasing the life span of HIV-positive individuals [2] and is associated with a reduction in new infections [4–6].”
BackgroundSelf-citationLester, R. T., Ritvo, P., Mills, E. J., Kariri, A., Karanja, S., Chung, M. H., Jack, W., Habyarimana, J., Sadatsafavi, M., Najafzadeh, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61997-6 · Cited by 1,278
Tanser, F., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M.-L. (2013) · Science · doi:10.1126/science.1228160 · Cited by 796
Metadata
- Authors
- Montaner, J. S., Lima, V. D., Barrios, R., Yip, B., Wood, E., Kerr, T., Shannon, K., Harrigan, P. R., Hogg, R. S., Daly, P., & Kendall, P.
- Affiliations
- Providence Health Care (CA)
- Vancouver Coastal Health (CA)
- Government of British Columbia (CA)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 376
- Issue
- 9740
- Pages
- 532-539
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC2996043
- OpenAlex
- W2120953033
- Cited by
- 780
- References
- 44
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 13 · 2023: 9 · 2022: 15 · 2021: 37 · 2020: 36 · 2019: 30 · 2018: 38 · 2017: 71 · 2016: 64 · 2015: 72 · 2014: 88 · 2013: 101 · 2012: 93
- FWCI
- 60.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- cIRcle (University of British Columbia) (submittedVersion, cc-by-nc-nd)
- Funders
- GlaxoSmithKline
- Gilead Sciences
- ViiV Healthcare
- Michael Smith Health Research BC (R01DA021525)
- National Institutes of Health (R01DA021525).)
- Canadian Institutes of Health Research (RAA- 79918, R01-DA021525, MOP– 79297)
- National Institute on Drug Abuse (R01DA021525, DP1DA026182)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- highly active antiretroviral therapy, HIV transmission, HIV viral load, newly diagnosed HIV, HIV prevention, British Columbia, CD4 count, HIV testing trends
- MeSH terms
- British Columbia, Humans, RNA, Viral, HIV-1, HIV Infections, CD4 Lymphocyte Count, Viral Load, Antiretroviral Therapy, Highly Active
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. https://app.cochat.ai/papers/10.1016/s0140-6736(10)60936-1
- The paper
- Montaner, J. S., Lima, V. D., Barrios, R., Yip, B., Wood, E., Kerr, T., Shannon, K., Harrigan, P. R., Hogg, R. S., Daly, P., & Kendall, P. (2010). Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. The Lancet. https://doi.org/10.1016/s0140-6736(10)60936-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.